second generation 4-1BBζ EGFR806-EGFRt

Phase 1Cell therapy

second generation 4-1BBζ EGFR806-EGFRt is one of 32 biologic programs targeting Pediatric Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pediatric Solid TumorActive, not recruiting

Refractory Solid TumorsActive, not recruiting

Pediatric Solid TumorPhase 1

Active, not recruiting

Refractory Solid TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Refractory Solid Tumors

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 2

7 2

Votrient

Novartis

Phase 2

5 3

Oncovin

Eli Lilly

Phase 2

4 4

Keytruda

Merck & Co.

Phase 2

3 5

Opdivo

Bristol-Myers Squibb

Phase 2

3 6

Gemzar

Johnson & Johnson

Phase 2

2 7

Ibrance

Pfizer

Phase 2

1 8

Tecentriq

Roche

Phase 2

1 9

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 10

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2040

Phase 1Active, not recruiting

Pediatric Solid Tumor

NCT03618381

Q4 2040

Phase 1Active, not recruiting

Refractory Solid Tumors

NCT04483778

Clinical

Trials by Indication[1]

Refractory Solid Tumors1 trial

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Active, not recruiting·SSeattle Children's Hospital·Phase 1·NCT04483778·68 enrolled

Pediatric Solid Tumor1 trial

Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Active, not recruiting·SSeattle Children's Hospital·Phase 1·NCT03618381·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for second generation 4-1BBζ EGFR806-EGFRt. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — second generation 4-1BBζ EGFR806-EGFRt compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for second generation 4-1BBζ EGFR806-EGFRt. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seattle Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SSeattle Children's Hospital

second generation 4-1BBζ EGFR806-EGFRt

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2040

Q4 2040

Trials by Indication[1]

Refractory Solid Tumors1 trial

Pediatric Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News